Amneal Gets FDA Approval for Generic Hormone Drug
By Katherine Hamilton
Amneal Pharmaceuticals received approval from the Food and Drug Administration for lanreotide, a generic brand of a treatment for hormonal diseases.
The product, which will launch immediately, was designated by the FDA as a generic version of Somatuline Depot.
Lanreotide was approved as a 120-milligram injection. It is indicated to treat the hormone disorder acromegaly, as well as advanced gastro-enteropancreatic neuroendocrine tumors and carcinoid syndrome.
The drug helps control hormone levels and improves progression-free survival in eligible patients with cancer. It also reduces the need for rescue therapy in patients with carcinoid syndrome, which is caused by tumors releasing high amounts of hormones.
During the 12 months ended in July, annual sales for Somatuline Depot in the U.S. were $983 million, Amneal said. Somatuline is a registered trademark of the French drug company Ipsen Pharma.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 18, 2026 16:39 ET (20:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States